TL;DR
Intranasal vaccines offer a powerful way to stop pathogens at their point of entry, but they struggle with rapid clearance and low absorption in the nasal cavity. This review explores how diverse nanotechnology platforms—ranging from mucoadhesive chitosan to self-assembling virus-like particles—are being engineered to overcome these biological barriers and trigger robust mucosal immunity.
What Problem Does This Paper Address?
Most infectious diseases enter the body through mucosal surfaces, yet the majority of current vaccines are administered via intramuscular injection. While effective at generating systemic immunity, injectable vaccines often fail to elicit a strong local immune response (secretory IgA) at the "front lines" of infection.
Intranasal (IN) delivery is the most promising mucosal route, but it faces three major hurdles:
- Mucociliary Clearance: The nose is designed to wash away foreign particles within minutes.
- The Mucus Barrier: A thick, negatively charged layer that traps and neutralizes antigens.
- Low Immunogenicity: Antigens alone often fail to penetrate the epithelial layer to reach the Nasal-Associated Lymphoid Tissue (NALT).
The authors review how nanotechnology-driven delivery systems (NDDS) can shield antigens from degradation, extend their residence time in the nose, and actively target immune cells.
Methods
As a comprehensive review, the paper synthesizes recent preclinical and clinical data to categorize intranasal delivery systems based on their chemical and physical properties. The authors evaluate several classes of nanocarriers:
- Natural Polysaccharides: Focusing on Chitosan (highly mucoadhesive due to its positive charge), starch, and alginate.
- Synthetic Polymers: Specifically PLGA, known for its biocompatibility and sustained release profiles.
- Inorganic Nanoparticles: Such as Gold (AuNPs), which allow for precise control over antigen display and shape.
- Self-Assembling Systems: Including Nanogels, Lipopeptides, Liposomes, and Virus-Like Particles (VLPs) that mimic the structure of actual pathogens.
- Biological/Emulsion Systems: Nanoemulsions and Bacterial Spores (e.g., Bacillus subtilis) that act as both carriers and potent adjuvants.
Datasets
The paper does not introduce a new experimental dataset. Instead, it provides structured meta-data in the form of:
- Table 1: Currently approved intranasal vaccines (e.g., FluMist, BBV154).
- Tables 2-4: Summaries of preclinical studies across various species (mice, pigs, macaques) for diseases like SARS-CoV-2, Influenza, and Toxoplasmosis.
- Table 5: A detailed list of current clinical trials (Phase 1-4) for intranasal candidates targeting HIV, Norovirus, RSV, and Anthrax.
Key Insights and Ideas
- The "Stickiness" Factor: Mucoadhesion is the primary driver of success. Cationic (positively charged) particles like chitosan are particularly effective because they bind to the anionic (negatively charged) sialic acid in nasal mucus, preventing the vaccine from being swallowed or sneezed out too quickly.
- Dual-Role Carriers: Many modern nanocarriers are no longer "passive" boxes. Materials like certain lipids and polysaccharides inherently possess adjuvant properties, meaning they simultaneously deliver the cargo and "wake up" the innate immune system.
- M-Cell Targeting: The "holy grail" of IN delivery is reaching the M cells within the NALT. Nanoparticles can be surface-modified with ligands to specifically target these cells, facilitating direct transport of the vaccine to underlying dendritic cells and B cells.
- The Brain Proximity Risk: The review highlights a unique safety concern: the olfactory bulb provides a direct pathway from the nasal cavity to the central nervous system. This necessitates rigorous neurotoxicity screening for any IN nano-formulation.
Key Results
- Clinical Proof of Concept: The success of the COVID-19 vaccine BBV154 (adenovirus vector) and FluMist (live attenuated) demonstrates that the nasal route is viable for global health crises.
- Superior Protection: Preclinical data consistently show that nano-formulated IN vaccines produce higher levels of secretory IgA (sIgA) in the lungs and nasal passages compared to traditional injections, providing better "sterilizing immunity" that prevents transmission.
- Breadth of Response: New "nanogel" and "VLP" platforms are showing the ability to induce Th17 and tissue-resident memory T cells, which are critical for long-term protection against respiratory pathogens.
Limitations and Future Work
- The Translation Gap: While results in mice are stellar, the human nasal anatomy is significantly different (larger surface area, different airflow patterns), making it difficult to predict human dosage from animal models.
- Manufacturing Scalability: Complex systems like VLPs or chemically modified chitosan are difficult and expensive to produce at the scale required for global distribution.
- Safety Standardization: There is a lack of standardized toxicity assays specifically for nasal nanomedicines. The authors call for more long-term studies on how these particles interact with the blood-brain barrier.
- Future Direction: The authors suggest that the next generation of IN vaccines will likely combine nanocarriers with molecular adjuvants (like STING agonists) to achieve "spatiotemporal synchronization" of antigen presentation and immune activation.
Summary updated